Mikael Sunnaker
Overview
Explore the profile of Mikael Sunnaker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sunnaker M, Bhattacharya C, Nelander K, Aurell M, Heijer M, Collen A, et al.
Clin Drug Investig
. 2024 Nov;
44(11):863-874.
PMID: 39495467
Background And Objective: Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic dysfunction-associated steatohepatitis and chronic obstructive pulmonary disease....
2.
Johnson M, Lin Y, Schmidt H, Sunnaker M, van Maanen E, Huang X, et al.
Br J Clin Pharmacol
. 2024 Aug;
90(12):3263-3276.
PMID: 39160062
Aims: Osimertinib is a third-generation, irreversible, central nervous system-active, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with efficacy in EGFR-mutated non-small cell lung cancer (NSCLC). We assessed the...
3.
Bhattacharya C, Pizzato P, Heijer M, Sunnaker M, Holden J, Trebski M, et al.
Br J Clin Pharmacol
. 2024 Aug;
90(12):3212-3220.
PMID: 39134325
Aims: Mitiperstat is a novel, highly potent myeloperoxidase inhibitor being evaluated in patients with cardio-metabolic disease (phase 2). These patients often have impaired renal function, which may affect mitiperstat pharmacokinetics....
4.
Mercier A, Ueckert S, Sunnaker M, Hamren B, Ambery P, Greasley P, et al.
Clin Pharmacol Ther
. 2024 Jul;
116(3):653-664.
PMID: 38961664
Getting the dose right is a key challenge in drug development; model-informed drug development (MIDD) provides powerful tools to shape dose strategies and inform decision making. In this tutorial, the...
5.
Parkinson J, Sundell J, Rekic D, Nelander K, Ericsson H, Ebrahimi A, et al.
Pharmacol Res Perspect
. 2024 Mar;
12(2):e1184.
PMID: 38445541
Mitiperstat is a myeloperoxidase inhibitor in clinical development for treatment of patients with heart failure and preserved or mildly reduced ejection fraction, non-alcoholic steatohepatits and chronic obstructive pulmonary disease. We...
6.
Mercier A, Sunnaker M, Ueckert S, Pawlik T, Henricson E, Molodetskyi O, et al.
Clin Pharmacokinet
. 2023 Oct;
62(12):1713-1724.
PMID: 37801266
Background And Objective: Zibotentan, a selective endothelin A receptor antagonist, is in development for chronic liver and kidney disease. The pharmacokinetics (PK) of zibotentan were previously investigated in patients with...
7.
Heerspink H, Greasley P, Ahlstrom C, Althage M, Dwyer J, Law G, et al.
Nephrol Dial Transplant
. 2023 Aug;
39(3):414-425.
PMID: 37632201
Background: Sodium-glucose co-transporter 2 inhibitors (SGLT2is) are part of the standard of care for patients with chronic kidney disease (CKD), both with and without type 2 diabetes. Endothelin A (ETA)...
8.
Leander J, Sunnaker M, Rekic D, Aksenov S, Eriksson U, Johansson S, et al.
J Pharmacokinet Pharmacodyn
. 2021 Mar;
48(4):525-541.
PMID: 33728547
Verinurad, a uric acid transporter 1 (URAT1) inhibitor, lowers serum uric acid by promoting its urinary excretion. Co-administration with a xanthine oxidase inhibitor (XOI) to simultaneously reduce uric acid production...
9.
Gargiulo G, Valgimigli M, Sunnaker M, Vranckx P, Frigoli E, Leonardi S, et al.
Rev Esp Cardiol (Engl Ed)
. 2020 Mar;
73(11):893-901.
PMID: 32151464
Introduction And Objectives: Patients who are vulnerable to hemodynamic or electrical disorders (VP) are often excluded from clinical trials and data on the optimal access-site or antithrombotic treatment are limited....
10.
Rybinski M, Moller S, Sunnaker M, Lormeau C, Stelling J
BMC Bioinformatics
. 2020 Jan;
21(1):34.
PMID: 31996136
Background: To develop mechanistic dynamic models in systems biology, one often needs to identify all (or minimal) representations of the biological processes that are consistent with experimental data, out of...